259 related articles for article (PubMed ID: 19902390)
1. Pharmacogenetics and pharmacoepigenetics of gemcitabine.
Candelaria M; de la Cruz-Hernández E; Pérez-Cárdenas E; Trejo-Becerril C; Gutiérrez-Hernández O; Dueñas-González A
Med Oncol; 2010 Dec; 27(4):1133-43. PubMed ID: 19902390
[TBL] [Abstract][Full Text] [Related]
2. Integrating pharmacogenetics into gemcitabine dosing--time for a change?
Ciccolini J; Mercier C; Dahan L; André N
Nat Rev Clin Oncol; 2011 Feb; 8(7):439-44. PubMed ID: 21304503
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology and pharmacogenetics of gemcitabine.
Wong A; Soo RA; Yong WP; Innocenti F
Drug Metab Rev; 2009; 41(2):77-88. PubMed ID: 19514966
[TBL] [Abstract][Full Text] [Related]
4. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
Metharom E; Galettis P; Manners S; Jelinek M; Liauw W; de Souza PL; Hoskins JM; Links M
Asia Pac J Clin Oncol; 2011 Mar; 7(1):65-74. PubMed ID: 21332653
[TBL] [Abstract][Full Text] [Related]
5. Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine).
Ruiz van Haperen VW; Veerman G; van Moorsel CJ; Peters GJ
Adv Exp Med Biol; 1998; 431():637-40. PubMed ID: 9598143
[No Abstract] [Full Text] [Related]
6. Gemcitabine: a critical nucleoside for cancer therapy.
Gesto DS; Cerqueira NM; Fernandes PA; Ramos MJ
Curr Med Chem; 2012; 19(7):1076-87. PubMed ID: 22257063
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.
Ciccolini J; Serdjebi C; Peters GJ; Giovannetti E
Cancer Chemother Pharmacol; 2016 Jul; 78(1):1-12. PubMed ID: 27007129
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y
Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.
Li L; Fridley BL; Kalari K; Jenkins G; Batzler A; Weinshilboum RM; Wang L
PLoS One; 2009 Nov; 4(11):e7765. PubMed ID: 19898621
[TBL] [Abstract][Full Text] [Related]
10. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Mitra AK; Kirstein MN; Khatri A; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK
Pharmacogenomics; 2012 Jul; 13(9):1009-21. PubMed ID: 22838949
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic.
Bookman MA
Int J Gynecol Cancer; 2005; 15 Suppl 1():12-7. PubMed ID: 15839953
[TBL] [Abstract][Full Text] [Related]
12. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
[No Abstract] [Full Text] [Related]
13. Toxicity on human hemopoietic progenitors of 2'-2'-difluoro-2'deoxycytidine (gemcitabine).
Botta M; Castello G; Ballarino P; Arboscello E; Lerza R; Mencoboni M; Pannacciulli I
Anticancer Res; 1998; 18(2A):1037-42. PubMed ID: 9615761
[TBL] [Abstract][Full Text] [Related]
14. [Gemcitabine and pemetrexed update].
Spano JP; Bay JO
Bull Cancer; 2007; 94 Spec No Actualites():S83. PubMed ID: 17845975
[No Abstract] [Full Text] [Related]
15. Cellular pharmacology of gemcitabine.
Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.
Danesi R; Altavilla G; Giovannetti E; Rosell R
Pharmacogenomics; 2009 Jan; 10(1):69-80. PubMed ID: 19102717
[TBL] [Abstract][Full Text] [Related]
17. Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer.
Vandana M; Sahoo SK
Biomaterials; 2010 Dec; 31(35):9340-56. PubMed ID: 20851464
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine: a case study for clinical benefit.
Von Hoff DD
Semin Oncol; 1996 Oct; 23(5 Suppl 10):1-2. PubMed ID: 8893875
[No Abstract] [Full Text] [Related]
19. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment.
Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Ohtsuka H; Kamiie J; Abe T; Unno M; Terasaki T
Mol Pharm; 2015 Sep; 12(9):3282-91. PubMed ID: 26280109
[TBL] [Abstract][Full Text] [Related]
20. [MMW drug award for gemcitabine. Cytostatic drug with growing indications].
Füessl HS
MMW Fortschr Med; 2006 Nov; 148(45):6-7. PubMed ID: 17615737
[No Abstract] [Full Text] [Related]
[Next] [New Search]
